{
    "nct_id": "NCT04505826",
    "official_title": "A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Must have received at least 1 prior hormonal regimen and at least 6 months of a prior continuous endocrine therapy for locally advanced or metastatic disease\n* Must not have received prior oral endocrine therapy < 2 weeks prior to first dose\n* Must not have received prior, chemotherapy in 2 weeks or within 5 half-lives whichever is earlier, antibody therapy within 4 weeks or investigational therapy within 4 weeks or 5 half-lives whichever is earlier, prior to the first dose\n* Adequate hepatic function\n* Adequate renal function\n* Normal coagulation panel\n* Willingness to use effective contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Gastrointestinal disease\n* Significant renal disease\n* Significant cardiovascular disease\n* Significant ECG abnormalities\n* Ongoing systemic bacterial, fungal, or viral infection (requiring antimicrobial therapy)\n* Pregnancy or breastfeeding",
    "miscellaneous_criteria": ""
}